Citations

Mayo Clinic

Clear

13616 citation(s) found for "_, _".

A Candidate Gene Study of Folate-Associated One Carbon Metabolism Genes and Colorectal Cancer Risk
Levine, A. Joan, Figueiredo, Jane C. , Conti, David V. , Kennedy, Kathleen A. , Duggan, David , Poynter, Jenny N. , Martinez, Maria Elena, Haile, Robert W. , Lee, Won , Campbell, Peter T. , Newcomb, Polly A. , Hopper, John L. , Marchand, Loı̈c Le , Baron, John A. , Limburg, Paul J. , Ulrich, Cornelia M. , Haile, Robert W , Conti, David V

Cancer Epidemiology, Biomarkers & Prevention | July 8, 2010 | Volume: 19 | Issue: 7 | Pages: 1812-1821

10.1158/1055-9965.epi-10-0151 | PMID 20615890 Get It

Abstract Background: Folate-associated one-carbon metabolism (FOCM) may play an important role in colorectal carcinogenesis. Variation in FOCM genes may explain some of the underlying risk of colorectal cancer. Methods: This study utilized data from 1,805 population-based colorectal cancer cases and 2,878 matched sibling controls from the Colon Cancer Family Registry. We used a comprehensive haplotype tagging single nucleotide polymorphism (tagSNP) approach to select 395 tagSNPs in 15 genes involved in folate and vitamin B12 metabolism. Genotyping was done using the Illumina GoldenGate or Sequenom platforms. Risk factor and dietary data were collected using self-completed questionnaires. Microsatellite instability (MSI) status was determined using standard techniques, and tumor subsite was obtained from pathology reports. The association between SNPs and colorectal cancer was assessed using conditional logistic regression with sibships as the matching factor and assuming a log additive or codominant model. Results: In the log additive model, two linked (r2 = 0.99) tagSNPs in the DHFR gene (rs1677693 and rs1643659) were associated with a significant decrease in colorectal cancer risk after correction for multiple testing (odds ratio, 0.87; 95% confidence interval, 0.71-0.94; P = 0.029; and odds ratio, 0.87; 95% confidence interval, 0.71-0.95; P = 0.034 for rs1677693 and rs1643659, respectively). These two linked (r2 = 0.99) tagSNPs and one tagSNP in the MTR gene (rs4659744) were significantly associated with reduced colorectal cancer risk only among individuals not using multivitamin supplements. Conclusions: Overall, we found only moderate evidence that genetic variation in 15 folate pathway genes may affect colorectal cancer risk except in non–multivitamin users. Impact: This study suggests that multivitamin supplement use may modify the association between folate pathway genes and colorectal cancer risk in a post-folic-acid-supplemented population. Cancer Epidemiol Biomarkers Prev; 19(7); 1812–21. ©2010 AACR.
Selective stimulation of colonic transit by the benzofuran 5HT 4 agonist, prucalopride, in healthy humans
Bouras, Ernest P., Camilleri, Michael , Burton, Duane D. , McKinzie, Sanna

Gut | June 30, 2010 | Volume: 44 | Issue: 5 | Pages: 682-686

10.1136/gut.44.5.682 | PMID 10205205 Get It

BACKGROUND Prucalopride (R093877) is a selective and specific 5HT 4 agonist, the first of a new chemical class of benzofurans, with gastrointestinal prokinetic activities in vitro. AIMS To evaluate the effects of prucalopride on gastrointestinal and colonic transit. METHODS A validated scintigraphic technique was used to measure gastrointestinal and colonic transit over 48 hours in 50 healthy volunteers. For seven days, each subject received a daily dose of 0.5, 1, 2, or 4 mg prucalopride, or placebo in a double blind, randomised fashion. The transit test was performed over the last 48 hours. RESULTS There were significant accelerations of overall colonic transit at 4, 8, 24, and 48 hours (p<0.05) and proximal colonic emptying t 1/2 (p<0.05). The 0.5, 2, and 4 mg doses of prucalopride were almost equally effective and accelerated colonic transit compared with placebo. Prucalopride did not significantly alter gastric emptying (p>0.5) or small bowel transit (overall p=0.12). The medication appeared to be well tolerated during the seven day treatment of healthy subjects. CONCLUSION Prucalopride accelerates colonic transit, partly by stimulating proximal colonic emptying, but does not alter gastric or small bowel transit in healthy human subjects. Prucalopride deserves further study in patients with constipation.
Medium term effects of a new 5HT 3 antagonist, alosetron, in patients with carcinoid diarrhoea
Saslow, Stuart B., Scolapio, James S. , Camilleri, Michael , Forstrom, Lee A., Thomforde, G. M., Burton, Duane D. , Rubin, Joseph, Pitot, Henry C., Zinsmeister, Alan R.

Gut | June 30, 2010 | Volume: 42 | Issue: 5 | Pages: 628-634

10.1136/gut.42.5.628 | PMID 9659155 Get It

Background —Carcinoid diarrhoea is associated with rapid small bowel and proximal colonic transit. Intravenous administration of a serotonin type 3 receptor (5HT 3 ) antagonist restores postprandial colonic tone towards normal in carcinoid patients. Aims —To evaluate the medium term effects of an oral 5HT 3 antagonist, alosetron, on symptoms, stool fat, and transit in patients with carcinoid diarrhoea. Methods —In 27 patients with carcinoid diarrhoea, symptoms were recorded daily and gastrointestinal transit was measured by scintigraphy in a three dose (0.1, 0.5, 2.0 mg, twice daily), randomised (1:1:1), parallel group, four week study. Placebo was given during the first week. Loperamide (2 mg capsules) was used as rescue medication. Results —There were numerical improvements in median diarrhoea score, stool weight, loperamide use, and overall colonic transit at four hours, but no overall significant drug effect was shown. Alosetron reduced the proximal colon emptying rate (p<0.05 in 20 evaluable comparisons), but did not significantly alter small bowel transit. Conclusions —Alosetron retardation of proximal colonic emptying in patients with carcinoid diarrhoea confirms the potential role of a 5HT 3 mechanism in this disorder. Doses of alosetron higher than 2.0 mg twice daily will be required for symptomatic benefit in carcinoid diarrhoea.
Serum Cytokine Analysis in a Positive Chemoprevention Trial: Selenium, Interleukin-2, and an Association with Squamous Preneoplastic Disease
Roth, Mark J., Katki, Hormuzd A. , Wei, Wenqiang , Qiao, You‐Lin , Bagni, Rachel, Wang, Guo-Qing , Whitby, Denise , Dong, Zhi-Wei, Giffen, Carol , Gail, Mitchell H. , Limburg, Paul J. , Taylor, Philip R. , Dawsey, Sanford M. , Katki, Hormuzd A

Cancer Prevention Research | June 30, 2010 | Volume: 3 | Issue: 7 | Pages: 810-817

10.1158/1940-6207.capr-09-0269 | PMID 20587703 Get It

Abstract This study represents a multiplex cytokine analysis of serum from a 10-month randomized, controlled trial of 238 subjects that investigated the effects of selenomethionine and/or celecoxib in subjects with mild or moderate esophageal squamous dysplasia. The original chemoprevention study found that, among those with mild dysplasia, selenomethionine treatment favorably altered dysplasia grade. The current analysis found that selenomethionine downregulated interleukin (IL)-2 by 9% (P = 0.04), whereas celecoxib downregulated IL-7 by 11% (P = 0.006) and upregulated IL-13 by 17% (P = 0.008). In addition, an increase in IL-7 tertile from baseline to t10 was significantly associated with an increase in dysplasia grade, both overall [odds ratio (OR), 1.47; P = 0.03] and among those with mild dysplasia at t0 (OR, 2.53; P = 0.001). An increase in IL-2 tertile from baseline to t10 was also nonsignificantly associated with worsening dysplasia for all participants (OR, 1.32; P = 0.098) and significantly associated with worsening dysplasia among those with mild dysplasia at baseline (OR, 2.0; P = 0.01). The association of increased IL-2 with worsening dysplasia remained significant in those on selenomethionine treatment who began the trial with mild dysplasia (OR, 2.52; P = 0.03). The current study shows that selenomethionine supplementation decreased serum IL-2 levels, whereas celecoxib treatment decreased IL-7 levels and increased IL-13 levels during a 10-month randomized chemoprevention trial. An increase in IL-2 or IL-7 was associated with increased severity of dysplasia over the course of the trial, especially in those who began the trial with mild dysplasia. The favorable effect of selenomethionine on esophageal dysplasia in the original trial may have been mediated in part by its effect in reducing the levels of IL-2. Cancer Prev Res; 3(7); 810–7. ©2010 AACR.
Hashimoto Thyroiditis: Part 2, Sonographic Analysis of Benign and Malignant Nodules in Patients With Diffuse Hashimoto Thyroiditis
Anderson, Lauren , Middleton, William D. , Teefey, Sharlene A. , Reading, Carl C., Langer, Jill E. , Desser, Terry S. , Szabunio, Margaret M. , Mandel, Susan J., Hildebolt, Charles F. , Cronan, John J.

American Journal of Roentgenology | June 21, 2010 | Volume: 195 | Issue: 1 | Pages: 216-222

10.2214/ajr.09.3680 | PMID 20566819 Get It

Hashimoto Thyroiditis: Part 1, Sonographic Analysis of the Nodular Form of Hashimoto Thyroiditis
Anderson, Lauren , Middleton, William D. , Teefey, Sharlene A. , Reading, Carl C., Langer, Jill E. , Desser, Terry S. , Szabunio, Margaret M. , Hildebolt, Charles F. , Mandel, Susan J., Cronan, John J.

American Journal of Roentgenology | June 21, 2010 | Volume: 195 | Issue: 1 | Pages: 208-215

10.2214/ajr.09.2459 | PMID 20566818 Get It

Successful Nonsurgical Treatment of Pneumomediastinum, Pneumothorax, Pneumoperitoneum, Pneumoretroperitoneum, and Subcutaneous Emphysema following ERCP
Fujii, Larissa L., Lau, A. , Fleischer, David E., Harrison, M. Edwyn

Gastroenterology Research and Practice | June 14, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-7

10.1155/2010/289135 | PMID 20631834 Get It

Complications related to endoscopic retrograde cholangiopancreatography (ERCP) include pancreatitis, hemorrhage, cholangitis, and perforation. ERCP-related perforation is uncommon, but mortality rates are high. Diagnosis requires a high clinical suspicion for early detection to allow optimal management of the perforation and a better prognosis. Treatment depends on the location and mechanism and increasingly involves nonoperative management. We report a case of successful nonsurgical treatment of a patient with extensive air involving the peritoneum, retroperitoneum, thorax, mediastinum, and subcutaneous tissues following an ERCP perforation.
Multichanneled Collagen Conduits for Peripheral Nerve Regeneration: Design, Fabrication, and Characterization
Yao, Li , Windebank, Anthony J. , Pandit, Abhay , Billiar, Kristen Lawrence

Tissue Engineering Part C: Methods | June 9, 2010 | Volume: 16 | Issue: 6 | Pages: 1585-1596

10.1089/ten.tec.2010.0152 | PMID 20528663 Get It

In the absence of donor tissues, conduits are needed for axons to regenerate across nerve defects, yet single-channel conduits may result in axonal dispersion, and multichannel synthetic polymer conduits have failed due to dimensional instability. The goal of this study was to create a robust collagen-based nerve conduit with multiple submillimeter-diameter channels to facilitate nerve guidance. Toward this goal, we have developed a novel multistep molding technique to create single-, four-, and seven-channel conduits from collagen and examined the effects of crosslinking with 0–60 mM (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide [EDC] in N -hydroxysuccinimide) on geometric, enzymatic, and thermal stability, mechanical properties, and cellular behavior. Multichannel collagen conduits crosslinked with 30 mM EDC and 10 mM N -hydroxysuccinimide demonstrated low degradation rate (∼10% at 2 days), high shrinkage temperature (>75°C), and constant channel morphology out to 30 days in saline. Neurite outgrowth remained unaffected from cultured dorsal root ganglia explants seeded on collagen scaffolds with up to 30 mM EDC crosslinking. Compared with single-channel conduits, multichannel collagen conduits showed superior structural compressive, tensile, and bending stiffness. Taken together, these results suggest that the crosslinked multichannel collagen conduits possess favorable material and mechanical properties for nerve regeneration applications.
Relation of vertebral deformities to bone density, structure, and strength
Melton, L. Joseph, Riggs, B. Lawrence, Keaveny, Tony M. , Achenbach, Sara J., Kopperdahl, David L. , Camp, Jon J. , Rouleau, P, Amin, Shreyasee , Atkinson, Elizabeth J. , Robb, Richard A., Therneau, Terry M. , Khosla, Sundeep , Khosla, Sundeep

Journal of Bone and Mineral Research | June 8, 2010 | Volume: 25 | Issue: 9 | Pages: 1922-1930

10.1002/jbmr.150 | PMID 20533526 Get It

Abstract Because they are not reliably discriminated by areal bone mineral density (aBMD) measurements, it is unclear whether minimal vertebral deformities represent early osteoporotic fractures. To address this, we compared 90 postmenopausal women with no deformity (controls) with 142 women with one or more semiquantitative grade 1 (mild) deformities and 51 women with any grade 2–3 (moderate/severe) deformities. aBMD was measured by dual-energy X-ray absorptiometry (DXA), lumbar spine volumetric bone mineral density (vBMD) and geometry by quantitative computed tomography (QCT), bone microstructure by high-resolution peripheral QCT at the radius (HRpQCT), and vertebral compressive strength and load-to-strength ratio by finite-element analysis (FEA) of lumbar spine QCT images. Compared with controls, women with grade 1 deformities had significantly worse values for many bone density, structure, and strength parameters, although deficits all were much worse for the women with grade 2–3 deformities. Likewise, these skeletal parameters were more strongly associated with moderate to severe than with mild deformities by age-adjusted logistic regression. Nonetheless, grade 1 vertebral deformities were significantly associated with four of the five main variable categories assessed: bone density (lumbar spine vBMD), bone geometry (vertebral apparent cortical thickness), bone strength (overall vertebral compressive strength by FEA), and load-to-strength ratio (45-degree forward bending ÷ vertebral compressive strength). Thus significantly impaired bone density, structure, and strength compared with controls indicate that many grade 1 deformities do represent early osteoporotic fractures, with corresponding implications for clinical decision making. © 2010 American Society for Bone and Mineral Research
Cancer Immunotherapy: Focusing on the Young, Neglecting The Old
Lustgarten, Joseph

Future Oncology | June 8, 2010 | Volume: 6 | Issue: 6 | Pages: 873-876

10.2217/fon.10.64 | PMID 20528222 Get It